Program
sitagliptin
Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.
Drug pageSitagliptin: every studyMany companies study it; this page follows only the 101 they lead. All 306 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 780 open or running | phase 4since Jan 28, 2009 | Jul 2, 2004 | none ahead |
| Ono Pharmaceuticalits history only | 50 open or running | phase 3since Aug 11, 2006 | Aug 11, 2006 | none ahead |
| ADIUMits history only | 40 open or running | no phasesince Aug 10, 2026 | Aug 10, 2026 | none ahead |
| Novo Nordiskits history only | 40 open or running | phase 4since Jan 24, 2012 | Jun 18, 2008 | none ahead |
| Bio-innovaits history only | 22 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Sep 13, 2012 | Jun 12, 2012 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 2since Aug 28, 2013 | Aug 28, 2013 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Jun 30, 2016 | Jun 30, 2016 | none ahead |
| Dong Wha Pharmaceuticalits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| KineMedits history only | 10 open or running | no phasesince Mar 23, 2010 | Mar 23, 2010 | none ahead |
Also a collaborator on its studies: Parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jan 3, 2007.
- Oct 27, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01462266 · 660 enrolled
- Nov 19, 2011Phase 3 study in Diabetes Mellitus, Type 2NCT01477853 · 166 enrolled
- Dec 1, 2011Phase 3 study in Diabetes MellitusNCT01485614 · 200 enrolled
- Mar 16, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01557504 · 25 enrolled
- Apr 19, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01582308 · 22 enrolled
- May 1, 20122 phase 3 studies in Diabetes Mellitus, Type 2NCT01590797, NCT01590771
- Aug 31, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01678820 · 299 enrolled
- Oct 4, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01702298 · 42 enrolled
- Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01760447 · 223 enrolled
- Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02099110 · 1,233 enrolled
- Dec 12, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02318693 · 53 enrolled
- Aug 25, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02532855 · 614 enrolled
- Apr 11, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02738879 · 746 enrolled
- Jun 1, 2016Phase 3 study in Diabetes Mellitus, Type 2NCT02791490 · 458 enrolled
- Jul 21, 2022Named sitagliptinINNProposed as its International Nonproprietary Name in WHO's List 127
TargetBeta
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 78 Merck leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02791490Diabetes Mellitus, Type 2 | 3 | Completed | Feb 1, 2018 | 458 |
| NCT02738879Diabetes Mellitus, Type 2 | 3 | Completed | Jan 22, 2018 | 746 |
| NCT02532855Diabetes Mellitus, Type 2 | 3 | Completed | Oct 10, 2017 | 614 |
| NCT02318693Diabetes Mellitus, Type 2 | 4 | Completed | Dec 15, 2015 | 53 |
| NCT02099110Diabetes Mellitus, Type 2 | 3 | Completed | May 26, 2016 | 1,233 |
| NCT01760447Diabetes Mellitus, Type 2 | 3 | Completed | Sep 17, 2019 | 223 |
| NCT01702298Diabetes Mellitus, Type 2 | 3 | Completed | May 29, 2013 | 42 |
| NCT01678820Diabetes Mellitus, Type 2 | 3 | Terminated | Nov 1, 2013 | 299 |
| NCT01590797Diabetes Mellitus, Type 2 | 3 | Completed | Jun 11, 2014 | 467 |
| NCT01590771Diabetes Mellitus, Type 2 | 3 | Completed | Jun 10, 2014 | 498 |
| NCT01582308Diabetes Mellitus, Type 2 | 1 | Completed | Dec 4, 2012 | 22 |
| NCT01557504Diabetes Mellitus, Type 2 | 1 | Completed | Apr 29, 2014 | 25 |
| NCT01485614Diabetes Mellitus | 3 | Completed | Oct 9, 2019 | 200 |
| NCT01477853Diabetes Mellitus, Type 2 | 3 | Terminated | Dec 4, 2012 | 166 |
| NCT01462266Diabetes Mellitus, Type 2 | 3 | Completed | Jun 6, 2013 | 660 |
| NCT01405911Glucose Intolerance | 2 | Completed | Apr 9, 2012 | 242 |
| NCT01340768Diabetes Mellitus, Type 2 | 3 | Completed | Sep 21, 2011 | 870 |
| NCT01296412Diabetes Mellitus, Type 2 | 3 | Completed | Feb 29, 2012 | 653 |
| NCT01189890Diabetes Mellitus, Type 2 | 3 | Completed | Oct 31, 2012 | 480 |
| NCT01177384Diabetes Mellitus, Type 2 | 3 | Completed | Mar 25, 2013 | 380 |
| NCT01131182Diabetes Mellitus, Type 2 | 4 | Completed | Nov 4, 2010 | 1,147 |
| NCT01093794Diabetes Mellitus, Type 2 | 1 | Completed | Jun 2010 | 28 |
| NCT01076088Diabetes Mellitus, Type 2 | 3 | Completed | Dec 24, 2012 | 744 |
| NCT01076075Diabetes Mellitus, Type 2 | 3 | Completed | Jul 11, 2011 | 427 |
| NCT01034111Diabetes Mellitus, Type 2 | 3 | Completed | Oct 4, 2010 | 30 |
| NCT01028391Diabetes Mellitus, Type 2 | 3 | Completed | Jan 1, 2009 | 317 |
| NCT00993187Diabetes Mellitus, Type 2 | 4 | Completed | Oct 29, 2013 | 292 |
| NCT00975052Diabetes Mellitus, Type 2 | 1 | Completed | Mar 2006 | 16 |
| NCT00944450Diabetes Mellitus, Type 2 | 1 | Completed | Sep 2004 | 12 |
| NCT00929201Diabetes Mellitus, Type 2 | 1 | Completed | Mar 2008 | 61 |
| NCT00888238Diabetes Mellitus, Type 2 | 1 | Completed | Jun 10, 2009 | 12 |
| NCT00885352Diabetes Mellitus, Type 2 | 3 | Completed | Nov 10, 2010 | 313 |
| NCT00875394Diabetes Mellitus, Type 2 | 3 | Completed | Jun 27, 2008 | 68 |
| NCT00833027Diabetes Mellitus | 4 | Completed | Oct 30, 2009 | 608 |
| NCT00832624Diabetes Mellitus, Type 2 | 4 | Terminated | Sep 2, 2009 | 10 |
| NCT00832390Diabetes Mellitus | 4 | Completed | Jul 11, 2008 | 29 |
| NCT00830076Diabetes Mellitus, Type 2 | 1 | Completed | Apr 30, 2009 | 18 |
| NCT00813995Diabetes Mellitus, Type 2 | 3 | Completed | Aug 9, 2010 | 395 |
| NCT00790205Diabetes Mellitus, Type 2 | 3 | Completed | Mar 30, 2015 | 14,671 |
| NCT00758069Diabetes Mellitus, Type 2 | 2 | Completed | Feb 13, 2006 | 80 |
| NCT00730275Diabetes Mellitus, Type 2 | 1 | Completed | Dec 30, 2010 | 35 |
| NCT00722371Diabetes Mellitus, Type 2 | 3 | Completed | Oct 26, 2010 | 1,615 |
| NCT00704132Diabetes Mellitus, Type 2 | 1 | Completed | Apr 28, 2010 | 57 |
| NCT00701090Diabetes Mellitus, Type 2 | 3 | Completed | Oct 2009 | 1,035 |
| NCT00696826Hepatic Insufficiency | 1 | Completed | May 2004 | 20 |
| NCT00642798Diabetes Mellitus, Type 2 | 1 | Completed | Mar 2008 | 16 |
| NCT00631488Diabetes Mellitus, Type 2 | 2 | Completed | Jan 2009 | 146 |
| NCT00545584Diabetes Mellitus, Type 2 | 3 | Completed | Nov 19, 2009 | 1,512 |
| NCT00541775Diabetes Mellitus, Type 2 | 3 | Completed | Mar 2007 | 273 |
| NCT00541450Diabetes Mellitus, Type 2 | 3 | Completed | Jan 8, 2010 | 492 |
| NCT00541229Diabetes Mellitus, Type 2 | 1 | Completed | Jun 17, 2008 | 103 |
| NCT00532935Diabetes Mellitus, Type 2 | 3 | Completed | Oct 23, 2009 | 517 |
| NCT00511108Diabetes Mellitus, Type 2 | 1 | Completed | Feb 24, 2009 | 211 |
| NCT00509262Diabetes Mellitus, Type 2 | 3 | Completed | Mar 16, 2011 | 426 |
| NCT00509236Diabetes Mellitus, Type 2 | 3 | Completed | Mar 14, 2011 | 129 |
| NCT00482079Diabetes Mellitus, Type 2 | 2 | Completed | Aug 25, 2004 | 743 |
| NCT00481663Diabetes Mellitus, Type 2 | 2 | Completed | Jul 21, 2004 | 555 |
| NCT00482729Diabetes Mellitus, Type 2 | 3 | Completed | Nov 3, 2008 | 1,246 |
| NCT00449930Diabetes Mellitus, Type 2 | 3 | Completed | Jul 25, 2008 | 1,050 |
| NCT00418366Renal Insufficiency | 1 | Completed | Mar 2003 | 24 |
How it is read
Names in the registry
- “Sitagliptin”, 33 entries
- “sitagliptin phosphate”, 18 entries
- “sitagliptin”, 15 entries
- “Sitagliptin phosphate”, 10 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: MK0431.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 106 studies
- Diabetes Mellitus, 2 studies
- Glucose Intolerance, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.